BethAnn McLaughlin
Faculty Member
Last active: 4/25/2016

Profile

My laboratory is interested in studying cell signaling pathways related to neurodegeneration and protection. We have two major research programs ongoing in the lab. The first is the study of how a short, sublethal ischemic event in the brain can lead to subsequent neuronal resistance to a severe stroke, a phenomenon commonly referred to as ischemic preconditioning. In order to investigate the cellular and molecular events that contribute to this process, we have developed several in vivo and in vitro systems in which cortical neuronal cells can be rendered less sensitive to excitotoxic cell death following a nontoxic exposure to mild chemical ischemia or hypoxia. We are using a variety of biochemical, molecular and proteomic approaches to both enhance our understanding of signaling pathways that we have already determined to be critical for the expression of preconditioning as well as to identify new protein targets which may contribute to this phenomenon. Our findings suggest that intervention against neurological events which result in subtoxic activation of traditional cell death pathways may actually increase vulnerability to subsequent stressors. Other ongoing lab projects include understanding how classical biochemical changes in ion homeostasis (specifically zinc, calcium and potassium homeostasis) induce the molecular pathways associated with apoptotic cell death. In this work we established a novel link between ROS and zinc induced activation of MAPKs and opening of potassium channels that are associated with apoptotic cell death. The goal of my research program is to understand the endogenous pathways associated with neurodegeneration and protection to develop novel therapeutics for stroke, cerebral palsy and other degenerative conditions. In addition, these studies investigate signaling pathways which provide protective mechanisms against other forms of cell death.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Silent Cerebral Small Vessel Disease in Restless Legs Syndrome. Ferri R, Cosentino FI, Moussouttas M, Lanuzza B, Aricò D, Bagai K, Wang L, McLaughlin B, Walters AS (2016) Sleep 39(7): 1371-7
    › Primary publication · 27091527 (PubMed) · PMC4909619 (PubMed Central)
  2. Assembly Dynamics and Stoichiometry of the Apoptosis Signal-regulating Kinase (ASK) Signalosome in Response to Electrophile Stress. Federspiel JD, Codreanu SG, Palubinsky AM, Winland AJ, Betanzos CM, McLaughlin B, Liebler DC (2016) Mol Cell Proteomics 15(6): 1947-61
    › Primary publication · 27006476 (PubMed) · PMC5083084 (PubMed Central)
  3. Intraarterial administration of norcantharidin attenuates ischemic stroke damage in rodents when given at the time of reperfusion: novel uses of endovascular capabilities. Khan IS, Odom M, Ehtesham M, Colvin D, Quarles CC, McLaughlin B, Singer RJ (2016) J Neurosurg 125(1): 152-9
    › Primary publication · 26544777 (PubMed) · PMC5338686 (PubMed Central)
  4. CHIP Is an Essential Determinant of Neuronal Mitochondrial Stress Signaling. Palubinsky AM, Stankowski JN, Kale AC, Codreanu SG, Singer RJ, Liebler DC, Stanwood GD, McLaughlin B (2015) Antioxid Redox Signal 23(6): 535-49
    › Primary publication · 25602369 (PubMed) · PMC4544748 (PubMed Central)
  5. Poised for success: implementation of sound conditioning strategies to promote endogenous protective responses to stroke in patients. McLaughlin B, Gidday JM (2013) Transl Stroke Res 4(1): 104-13
    › Primary publication · 24323191 (PubMed) · PMC4227500 (PubMed Central)
  6. Enrichment of elevated plasma F2t-isoprostane levels in individuals with autism who are stratified by presence of gastrointestinal dysfunction. Gorrindo P, Lane CJ, Lee EB, McLaughlin B, Levitt P (2013) PLoS One 8(7): e68444
    › Primary publication · 23844202 (PubMed) · PMC3700867 (PubMed Central)
  7. Redox modification of proteins as essential mediators of CNS autophagy and mitophagy. Lizama-Manibusan B, McLaughlin B (2013) FEBS Lett 587(15): 2291-8
    › Primary publication · 23773928 (PubMed) · PMC5125300 (PubMed Central)
  8. Metabolic multianalyte microphysiometry reveals extracellular acidosis is an essential mediator of neuronal preconditioning. McKenzie JR, Palubinsky AM, Brown JE, McLaughlin B, Cliffel DE (2012) ACS Chem Neurosci 3(7): 510-8
    › Primary publication · 22860220 (PubMed) · PMC3399578 (PubMed Central)
  9. Haploinsufficiency of the E3 ubiquitin ligase C-terminus of heat shock cognate 70 interacting protein (CHIP) produces specific behavioral impairments. McLaughlin B, Buendia MA, Saborido TP, Palubinsky AM, Stankowski JN, Stanwood GD (2012) PLoS One 7(5): e36340
    › Primary publication · 22606257 (PubMed) · PMC3350526 (PubMed Central)
  10. The role of central nervous system development in late-onset neurodegenerative disorders. Palubinsky AM, Martin JA, McLaughlin B (2012) Dev Neurosci 34(2-3): 129-39
    › Primary publication · 22572535 (PubMed) · PMC6065248 (PubMed Central)
  11. Perioperative plasma F(2)-Isoprostane levels correlate with markers of impaired ventilation in infants with single-ventricle physiology undergoing stage 2 surgical palliation on the cardiopulmonary bypass. Albers E, Donahue BS, Milne G, Saville BR, Wang W, Bichell D, McLaughlin B (2012) Pediatr Cardiol 33(4): 562-8
    › Primary publication · 22327227 (PubMed) · PMC3641818 (PubMed Central)
  12. The fatty acid oxidation product 15-A3t-isoprostane is a potent inhibitor of NFκB transcription and macrophage transformation. Brooks JD, Musiek ES, Koestner TR, Stankowski JN, Howard JR, Brunoldi EM, Porta A, Zanoni G, Vidari G, Morrow JD, Milne GL, McLaughlin B (2011) J Neurochem 119(3): 604-16
    › Primary publication · 21838782 (PubMed) · PMC3640263 (PubMed Central)
  13. Assessing neuronal bioenergetic status. Zeiger SL, Stankowski JN, McLaughlin B (2011) Methods Mol Biol : 215-35
    › Primary publication · 21815069 (PubMed) · PMC3678904 (PubMed Central)
  14. p66(shc)'s role as an essential mitophagic molecule in controlling neuronal redox and energetic tone. Kleman AM, Brown JE, Zeiger SL, Hettinger JC, Brooks JD, Holt B, Morrow JD, Musiek ES, Milne GL, McLaughlin B (2010) Autophagy 6(7): 948-9
    › Primary publication · 20724835 (PubMed) · PMC3679093 (PubMed Central)
  15. C-terminus of heat shock cognate 70 interacting protein increases following stroke and impairs survival against acute oxidative stress. Stankowski JN, Zeiger SL, Cohen EL, DeFranco DB, Cai J, McLaughlin B (2011) Antioxid Redox Signal 14(10): 1787-801
    › Primary publication · 20677910 (PubMed) · PMC3078511 (PubMed Central)
  16. Neuron specific metabolic adaptations following multi-day exposures to oxygen glucose deprivation. Zeiger SL, McKenzie JR, Stankowski JN, Martin JA, Cliffel DE, McLaughlin B (2010) Biochim Biophys Acta 1802(11): 1095-104
    › Primary publication · 20656023 (PubMed) · PMC2943006 (PubMed Central)
  17. Essential role of the redox-sensitive kinase p66shc in determining energetic and oxidative status and cell fate in neuronal preconditioning. Brown JE, Zeiger SL, Hettinger JC, Brooks JD, Holt B, Morrow JD, Musiek ES, Milne G, McLaughlin B (2010) J Neurosci 30(15): 5242-52
    › Primary publication · 20392947 (PubMed) · PMC2869196 (PubMed Central)
  18. New approaches to neuroprotection in infant heart surgery. Albers EL, Bichell DP, McLaughlin B (2010) Pediatr Res 68(1): 1-9
    › Primary publication · 20351657 (PubMed) · PMC2921700 (PubMed Central)
  19. Neurotoxic lipid peroxidation species formed by ischemic stroke increase injury. Zeiger SL, Musiek ES, Zanoni G, Vidari G, Morrow JD, Milne GJ, McLaughlin B (2009) Free Radic Biol Med 47(10): 1422-31
    › Primary publication · 19699297 (PubMed) · PMC2767385 (PubMed Central)
  20. Manganese exposure is cytotoxic and alters dopaminergic and GABAergic neurons within the basal ganglia. Stanwood GD, Leitch DB, Savchenko V, Wu J, Fitsanakis VA, Anderson DJ, Stankowski JN, Aschner M, McLaughlin B (2009) J Neurochem 110(1): 378-89
    › Primary publication · 19457100 (PubMed) · PMC2737271 (PubMed Central)
  21. Wagging the dog--moving closer to features defined by basic scientists, the protection of prodromal transient ischaemic attacks reveals itself. McLaughlin BA, Kirshner H (2008) Eur J Neurol 15(8): 755-6
    › Primary publication · 18684305 (PubMed) · PMC2869204 (PubMed Central)
  22. Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. Musiek ES, Brooks JD, Joo M, Brunoldi E, Porta A, Zanoni G, Vidari G, Blackwell TS, Montine TJ, Milne GL, McLaughlin B, Morrow JD (2008) J Biol Chem 283(29): 19927-35
    › Primary publication · 18490445 (PubMed) · PMC2459280 (PubMed Central)
  23. Electrophilic cyclopentenone isoprostanes in neurodegeneration. Musiek ES, McLaughlin B, Morrow JD (2007) J Mol Neurosci 33(1): 80-6
    › Primary publication · 17901550 (PubMed) · PMC2881560 (PubMed Central)
  24. Neurotoxic potential of depleted uranium effects in primary cortical neuron cultures and in Caenorhabditis elegans. Jiang GC, Tidwell K, McLaughlin BA, Cai J, Gupta RC, Milatovic D, Nass R, Aschner M (2007) Toxicol Sci 99(2): 553-65
    › Primary publication · 17636247 (PubMed)
  25. Killer proteases and little strokes--how the things that do not kill you make you stronger. O'Duffy AE, Bordelon YM, McLaughlin B (2007) J Cereb Blood Flow Metab 27(4): 655-68
    › Primary publication · 16896349 (PubMed) · PMC2881558 (PubMed Central)
  26. Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration. Musiek ES, Breeding RS, Milne GL, Zanoni G, Morrow JD, McLaughlin B (2006) J Neurochem 97(5): 1301-13
    › Primary publication · 16638022 (PubMed) · PMC2881557 (PubMed Central)
  27. Cyclopentenone eicosanoids as mediators of neurodegeneration: a pathogenic mechanism of oxidative stress-mediated and cyclooxygenase-mediated neurotoxicity. Musiek ES, Milne GL, McLaughlin B, Morrow JD (2005) Brain Pathol 15(2): 149-58
    › Primary publication · 15912888 (PubMed) · PMC2881556 (PubMed Central)
  28. The kinder side of killer proteases: caspase activation contributes to neuroprotection and CNS remodeling. McLaughlin B (2004) Apoptosis 9(2): 111-21
    › Primary publication · 15004508 (PubMed) · PMC2879070 (PubMed Central)
  29. Protein kinases and light: unlikely partners in a receptor localization puzzle. Leszkiewicz DN, McLaughlin BA, Aizenman E (2002) Physiol Behav 77(4-5): 533-6
    › Primary publication · 12526995 (PubMed)
  30. Inhibition of glutamate-induced mitochondrial depolarization by tamoxifen in cultured neurons. Hoyt KR, McLaughlin BA, Higgins DS, Reynolds IJ (2000) J Pharmacol Exp Ther 293(2): 480-6
    › Primary publication · 10773018 (PubMed)
  31. Methylmalonate toxicity in primary neuronal cultures. McLaughlin BA, Nelson D, Silver IA, Erecinska M, Chesselet MF (1998) Neuroscience 86(1): 279-90
    › Primary publication · 9692761 (PubMed)
  32. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. McLaughlin BA, Nelson D, Erecińska M, Chesselet MF (1998) J Neurochem 70(6): 2406-15
    › Primary publication · 9603205 (PubMed)
  33. Evidence of excitotoxicity in the brain of the ornithine carbamoyltransferase deficient sparse fur mouse. Robinson MB, Hopkins K, Batshaw ML, McLaughlin BA, Heyes MP, Oster-Granite ML (1995) Brain Res Dev Brain Res 90(1-2): 35-44
    › Primary publication · 8777776 (PubMed)
  34. CAG trinucleotide RNA repeats interact with RNA-binding proteins. McLaughlin BA, Spencer C, Eberwine J (1996) Am J Hum Genet 59(3): 561-9
    › Primary publication · 8751857 (PubMed) · PMC1914904 (PubMed Central)
  35. The sparse fur mouse as a model for gene therapy in ornithine carbamoyltransferase deficiency. Batshaw ML, Yudkoff M, McLaughlin BA, Gorry E, Anegawa NJ, Smith IA, Hyman SL, Robinson MB (1995) Gene Ther 2(10): 743-9
    › Primary publication · 8750014 (PubMed)